Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Compatible with Direct ELISA
Programmed death receptor ligand 1 (PD-L1, also called B7-H1) is a recently described B7 family member. To date, one specific receptor has been identified that can be ligated by PD-L1. This receptor, programmed death receptor 1 (PD-1), has been shown to negatively regulate T-cell receptor (TCR) signaling. Upon ligating its receptor, PD-L1 has been reported to decrease TCR-mediated proliferation and cytokine production. PD-L1 expression was found to be abundant on many murine and human cancers and could be further up-regulated upon IFN-gamma stimulation. Thus, PD-L1 might play an important role in tumor immune evasion.
CD137, also known as TNFRSF9 or 4-1BB, is an inducible costimulatory molecule expressed mainly on activated T cells. Its ligand, known as 4-1BBL, is expressed on activated macrophages, mature B cells, hematopoietic stem cells, and myeloid progenitor cells. CD137 signaling leads to maintaining the survival of activated T cells and CD8+ memory T cells, and clonal expansion of T cells, but also to suppressing myelopoiesis and dendritic cell development. Triggered CD137 induces a cytokine release profile regulating peripheral monocyte survival. Soluble forms of CD137 may provide negative control mechanism for some immune responses.
仅用于科研。不用于诊断过程。未经明确授权不得转售。